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More  than  40% of  all  deaths  in children  under  5 years  of  age  occur  during  the  neonatal  period:  the  ﬁrst
month  of  life.  Immunization  of  pregnant  women  has  proven  beneﬁcial  to both  mother  and  infant  by
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decreasing  morbidity  and  mortality.  With  an  increasing  number  of  immunization  trials  being  conducted
in  pregnant  women,  as  well  as roll-out  of  recommended  vaccines  to  pregnant  women,  there  is  a  need  to
clarify  details  of a neonatal  death.  This  manuscript  deﬁnes  levels  of certainty  of  a  neonatal  death,  related
to  the  viability  of  the  neonate,  who  conﬁrmed  the death,  and  the  timing  of  the  death  during  the  neonatal
period  and in relation  to immunization  of  the  mother.
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1. Preamble
1.1. Need for developing case deﬁnitions and guidelines for data
collection,  analysis, and presentation for neonatal death as an
adverse  event following immunization
Classiﬁcation of a child’s life into well-deﬁned periods has
become an important standardization to determine the care and
interventions necessary to increase the chances of child survival.
The neonatal period, which is globally accepted as beginning at
birth and ending at 28 completed days of life [1], is recognized as
the most vulnerable time in an infant’s life. Neonatal death has been
deﬁned by the World Health Organization (WHO) as “deaths among
Y license (http://creativecommons.org/licenses/by/4.0/).
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ive births during the ﬁrst 28 completed days of life” [1] which can
e further sub-divided into early neonatal deaths (deaths between
 and 7 completed days of birth) and late neonatal deaths (deaths
fter 7 days to 28 completed days of birth) [2].
Although global neonatal mortality rates have declined, from
1.9 (95% conﬁdence interval [CI] 31.9–32.8) deaths per 1000 live
irths in 1990 to 18.4 (95% CI 17.6–19.2) deaths per 1000 live births
n 2013 [3], this rate of decline (40%) lags the progress made in
ecreasing mortality in children aged 1–59 months (56%) [2]. The
ontribution of neonatal deaths (2.8 million in 2013) to the under-
 deaths has increased from 37.4% in 1990 to 41.6% in 2013 [2,3].
his trend has been projected to continue with anticipated further
apid declines in under-5 mortality. The ﬁrst week of life is the
ost critical for a neonate with 36% of neonatal deaths occurring
1 million) in the ﬁrst 24 h of life, 37% (1 million) occurring between
ays 1 and 7 of life and 27% (0.8 million) occurring between day 7
nd day 27 of life in 2013 [2,4].
The leading causes of neonatal death in 2013 globally
ere (i) preterm birth complications (742,400), (ii) intra-
artum related complications (neonatal encephalopathy from birth
sphyxia/trauma, 643,800), and (iii) neonatal sepsis (346,400) and
ther neonatal infections [3] including pneumonia, tetanus and
iarrhoea [2]. These global estimates mask the variations between
ountries and regions. For instance, only 7% of neonatal deaths
n high-income countries are caused by infectious diseases, com-
ared with 27% in Sub-Saharan Africa and 23% in Southern Asia [2]
J. Pathirana et al. / V028Figs. 1 and 2).
Immunization of pregnant women has been proven to be beneﬁ-
ial to the mother as well as the infant by decreasing morbidity and
ig. 1. Neonatal mortality rate in 100,000, age-standardized, both sexes, World Health O
ompare. Seattle, WA:  IHME, University of Washington, 2015. Available from http://ihmemortality during this vulnerable period [5,6]. With the huge suc-
cess of maternal tetanus vaccination for the prevention of neonatal
tetanus [7], there has been signiﬁcant resource allocation to vaccine
research and development for pregnant women. Currently immu-
nization of pregnant women  with tetanus and inﬂuenza vaccines is
widely recommended, with several countries also recommending
pertussis vaccination [8,9]. Other vaccines speciﬁcally targeting use
during pregnancy are in various stages of development and include
vaccines against Group B Streptococcus (GBS), Respiratory Syncy-
tial Virus (RSV) and Cytomegalovirus (CMV).
The association between receipt of a vaccine during pregnancy
and the subsequent death of the neonate requires documentation
and investigation to assess if there are potential vaccine safety
concerns which could have been associated with neonatal death.
Adverse pregnancy outcomes, including neonatal death, can coin-
cide temporally with immunization of pregnant women, and are
therefore reported as adverse events in clinical trials. Clinical tri-
als involving immunization of pregnant women have not, to date,
shown any increase in incidence of neonatal deaths in infants of
vaccine recipients compared to placebo recipients, or any increase
above local incidence rate [10–12].
Despite a WHO  deﬁnition of neonatal death being well accepted
globally, an established, detailed deﬁnition for use in maternal
immunization trials and surveillance following widespread imple-
mentation of maternal vaccinations does not currently exist. This is
a  missed opportunity, as data comparability across trials or surveil-
34 (2016) 6027–6037lance systems would facilitate data interpretation and promote the
scientiﬁc understanding of the event. The focus of vaccine safety
monitoring in currently licensed vaccines has been on foetal death,
rganization regions, 2013/Institute for Health Metrics and Evaluation (IHME). GBD
uw.org/3qjx (accessed 21.12.15).
Fig. 2. Neonatal mortality, percent of total deaths age-standardized, both sexes, World Health Organization regions, 2013/Institute for Health Metrics and Evaluation (IHME).
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J. Pathirana et al. / Vaccine 34 (2016) 6027–6037 6029BD  Compare. Seattle, WA:  IHME, University of Washington, 2015. Available from h
regnancy outcome (live birth or stillbirth), congenital anomalies
nd growth and development of the infant [12].
To determine association between neonatal death and maternal
mmunization, the background incidence of the adverse event
eeds to be established. Neonatal death reporting is a requirement
or national and international statistical comparisons allowing
ountries to review their achievements in the area of maternal and
eonatal health. It also allows measurement of effectiveness, or
ack thereof, of interventions and practices. Although the WHO  and
he International Classiﬁcation of Disease (ICD) have published
eﬁnitions and recommendations for recording and reporting of
ive births and neonatal deaths, reporting criteria varies between
ountries. This is largely dependent on the understanding of the
erm at local/regional level, availability of resources, cultural and
eligious perceptions and practices [1,12].
There are also differences in availability of trained health care
orkers and basic newborn care between high-income and low-
nd middle-income countries, which are not taken into account
hen global neonatal deaths are reported. Lack of clarity between
he various terminologies used to assess pregnancy outcomes by
ealth care workers leads to underreporting at several levels. Live
irth, abortion, foetal death, stillbirth, perinatal death and neona-
al death terms have deﬁnitions which may  overlap depending
n the setting. For instance, the WHO  recommends registration
f live births weighing at least 500 g or born at or after 22 weeks
estation [1]. However, in some cultures where neonatal survival
s uncertain, the baby remains unnamed and unregistered, and if
eath occurs in the early neonatal period, will not be recorded orihmeuw.org/3qjy (accessed 21.12.15).
reported as a live birth. Similarly a live birth at less than 28 weeks
of gestation in some countries will be reported as a miscarriage
rather than as a live birth due to variation in national reporting
criteria.
The case deﬁnitions for stillbirths, preterm delivery and neona-
tal infections in the context of maternal immunization are being
deﬁned by three other independent GAIA/Brighton Collaboration
working groups (available at: http://www.brightoncollaboration.
org).
Systematic review of the literature and stakeholder surveys
of adverse events following immunization during pregnancy and
the newborn period found a heterogeneity of outcome deﬁnitions,
safety assessment methods, and data collection methods, as well as
the lack of reporting consistency of safety data within and across
studies was  identiﬁed [13]. There is, therefore, a need to assess
vaccine safety in the newborn of a mother who receives immuniza-
tion during pregnancy; and a standardized deﬁnition of the adverse
event, neonatal death following maternal immunization is required
as well as data collection methods and tools. The WHO  Initiative
for Vaccine Research held a consultation to facilitate harmoniza-
tion of key events for monitoring vaccine safety in pregnant women
and newborn children in July 2014. In order to enable a standard-
ized assessment and to improve comparability the Neonatal Death
Working Group was established to deﬁne and develop guidelines to
inform vaccine safety monitoring in clinical studies, post-licensure
surveillance and in different geographical and cultural settings for
the event neonatal death following maternal immunization during
pregnancy.
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.2. Methods for the development of the case deﬁnition and
uidelines for data collection, analysis, and presentation for
eonatal death as an adverse event following maternal
mmunization
Following the process described in the overview paper [14]
s well as on the Brighton Collaboration Website http://www.
rightoncollaboration.org/internet/en/index/process.html, the
righton Collaboration Neonatal Death Working Group was  formed
n 2015 and included 15 members of (clinical, academic, public
ealth, industry) background. The composition of the work-
ng and reference group as well as results of the web-based
urvey completed by the reference group with subsequent dis-
ussions in the working group can be viewed at: http://www.
rightoncollaboration.org/internet/en/index/working groups.
tml.
To guide the decision-making for the case deﬁnition and guide-
ines, a narrative literature search without language restrictions
as performed using Medline and Embase, employing the key-
ords: neonatal death, newborn death, perinatal death, infant
eath and maternal immunization and maternal vaccination. The
earch resulted in the identiﬁcation of 972 Medline and Embase
eferences following the removal of duplicates. Six hundred and
inety seven abstracts were screened for possible reports of neona-
al death following maternal immunization. From these, 33 full text
rticles were reviewed in more detail, in order to identify stud-
es using case deﬁnitions or, in their absence, providing clinical
escriptions of the case material. This review resulted in a detailed
ummary of these articles, including information on the study type,
he vaccine, the diagnostic criteria or case deﬁnition put forth for
eonatal death.
Neonatal death as an adverse event following maternal immu-
ization was not commonly monitored. Outcomes such as preterm
irth, foetal death and stillbirth were the events that took precedent
n most maternal vaccine clinical trials. In studies that did measure
eonatal death, very few provided a referenced case deﬁnition.
.3. Rationale for selected decisions about the case deﬁnition of
eonatal death as an adverse event following immunization
.3.1. The neonatal period
Studies that did evaluate neonatal death, speciﬁed this event as
eath of a live born infant before 28 completed days of age [7,15–17].
his well recognized neonatal period is adopted in the neonatal
eath case deﬁnition as this period has consistently been used in
he literature reviewed, and in medical settings globally.
.3.2. The term death
The diagnosis of death or deﬁnition was not speciﬁed in any
iterature included. Death is regarded as the irreversible loss of
he capacity for consciousness, combined with irreversible loss of
he capacity to breathe including both cardiorespiratory death and
rain death [18]. This deﬁnition of death can be applicable in a vari-
ty of economic settings which can be further expanded on if the
ituation requires it such as in a medicolegal context.
.3.3. The term neonatal death
Only two papers reviewed sub-classiﬁed neonatal deaths into
arly deaths deﬁned as death of a newborn infant within the ﬁrst
eek or ﬁrst seven days of life [19,20]. Late neonatal death was
eﬁned as death of a live born infant between 1 and 4 weeks of life
20].
J. Pathirana et al. / Va030We  have further elaborated on this sub-classiﬁcation. Neonatal
eaths can be subdivided into (i) very early neonatal death (0 to
24 h), (ii) early neonatal deaths, occurring from the ﬁrst day to the
eventh day of life (≥24 h to <7 days), and (iii) late neonatal deaths,occurring after the seventh day but before 28 completed days of life
(≥7 to <28 days). In the literature and in practice, neonatal death
has only been classiﬁed into early (0–7 days) and late (>7 to 28
days) neonatal deaths [1,21]. However in the context of maternal
immunization and other factors associated with neonatal death
(intrapartum events, prematurity and infections) a third classiﬁ-
cation of very early death can enable a more detailed analysis of
adverse events surrounding a neonatal death.
1.3.4. The term live births
The term “live birth” was  infrequently mentioned in the liter-
ature as a prerequisite to classify a neonatal death. However, to
correctly differentiate a neonatal death from a stillbirth and appli-
cable to all geographic settings, the term live birth is necessary in
the case deﬁnition, and an understanding and agreement of the
term ‘live birth’ should be in place.
The Neonatal Death Working Group agreed to utilize the WHO
and ICD-10 deﬁnition of live birth, which is: ‘the complete expul-
sion or extraction from its mother of a product of conception,
irrespective of the duration of the pregnancy, which, after such sep-
aration, breathes or shows any other evidence of life – e.g. beating
of the heart, pulsation of the umbilical cord or deﬁnite move-
ment of voluntary muscles – whether or not the umbilical cord has
been cut or the placenta is attached. Each product of such a birth
is considered live born’ (http://www.who.int/healthinfo/statistics/
indmaternalmortality/en/) [22].
1.3.5. Timing of maternal immunization, birth and neonatal death
Three important time points need to be considered when
describing the association between immunization of a pregnant
woman and the adverse event, Neonatal death (i) date/time of
immunization of the mother during pregnancy, which should be
clearly recorded in antenatal records, (ii) date/time of birth of the
infant and (iii) date/time (age) of infant at death.
Death within the ﬁrst 24 h (<24 h) or ﬁrst day of life should be
recorded in units of completed minutes or hours of life. Deaths
occurring ≥24 h of life should be recorded in days, from day 1 to
27 completed days (International Statistical Classiﬁcation of Dis-
eases and Related Health Problems-10th Revision, ICD-10) [22]. It
is important to note that the ﬁrst day of life is not equivalent to age
1 day. A newborn is only 1 day old if it has survived beyond 24 h
of life. For example, if a newborn dies on the ﬁrst day of life at 6 h
after birth, age at death will be recorded as 6 h. If death occurs on
the 27th day of life, the age at death will be 26 days. If the newborn
dies on day 28 of life, age at death is 27 days.
A deﬁnition designed to be a suitable tool for describing relation-
ships requires ascertainment of the outcome (e.g. neonatal death)
independent from the exposure (e.g. immunizations). Therefore,
to avoid selection bias, a restrictive time interval from immuniza-
tion to Neonatal death is not an integral part of such a deﬁnition.
Instead, where feasible, details of this interval should be assessed
and reported as described in the data collection guidelines.
Further, neonatal death often occurs outside the controlled set-
ting of a clinical trial or hospital. In some settings it may  be
impossible to obtain a clear timeline of the event, particularly in less
developed or rural settings. The Brighton Collaboration case deﬁ-
nition avoids setting arbitrary time frames; however, the neonatal
period is a pre-deﬁned time period of the ﬁrst 28 days of life. In
order to avoid selecting against cases where exact number of days
may  not be available, less stringent measures of time have been
included in level 3 deﬁnitions.
34 (2016) 6027–60371.3.6. Related term(s) of neonatal death
Neonatal death is a very speciﬁc and terminal event, however,
the details available about the newborn and conﬁrmation of the
death may  vary considerably between regions. This case deﬁnition
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Fig. 3 illustrates the algorithm for the classiﬁcation of neonatal
death.
2.2. Neonatal death in a non-viable live birth
Level 1 of diagnostic certainty
ccines intended to accurately count the outcome neonatal death in var-
ous regions, and does not determine causality. Causality can often
nly be assessed at the time of data analysis, following collection
f medical history, examination and interventional data prior and
eading to the neonatal death. The case deﬁnition however includes
etails about the gestational age or weight, and conﬁrmation of
eath as this information was regarded as necessary by the working
roup to accurately deﬁne a neonatal death.
Neonatal death is deﬁned as the death of a live born infant,
egardless of gestational age at birth, within the ﬁrst 28 completed
ays of life. Each neonatal death can be further clariﬁed into viable
nd non-viable deaths depending on the gestational age at which
hey were born, and where they were born.
Medically-conﬁrmed death:  death conﬁrmed by suitable qual-
ﬁed medical or allied medical professional (including medical
octors, nurses, paramedics).
Non-medically-conﬁrmed death:  death conﬁrmed by non-
edically qualiﬁed person, including undertaker, community
ember, parent, family member, care-giver.
APGAR scoring: APGAR scoring of neonates in maternal immu-
ization studies was rarely described in the literature [16,17,23].
ell et al. [24] provided data on livebirths with 5-min APGAR below
. Prone to high levels of subjectivity, a low score does not indi-
ate death, as neonates with a 1 min  score of 0 may  score higher at
he 5 min  assessment. Due to this ambiguity, APGAR scores, though
ecessary to assess and document for appropriate management of
he newborn, has not been utilized in the case deﬁnition or levels of
iagnostic certainty as a pre-condition to classify a neonatal death.
Gestational age: Accurate gestational age measurement is a
ital aspect in monitoring the progress of pregnancy and in deci-
ion making on management. The most common methods for
etermining gestational age were last (normal) menstrual period
LMP) or ultra sound scanning which was well described in
he papers reviewed from well-resourced settings [15,20,25,26].
linical examination of pregnant woman has also been used
o determine gestational age [27]. Gestational age assessment
emains a challenge in poorly resourced settings where LMP  dates
re unreliable and access to early ultrasound scanning and special-
zed health care workers is limited. Therefore recommendations on
he methodology to determine gestational age applicable in various
eographic and resourced settings have been described in the levels
f diagnostic certainty (http://www.brightoncollaboration.org).
Viability: Reporting of neonatal deaths depends on reporting
riteria in countries/regions. Identifying viability of a live born
nfant, as deﬁned in the region/county, is an important precon-
ition to classify a neonatal death to enable comparison between
egions/countries.
Although the majority of papers reviewed did not clarify
 viable gestation, the lowest gestations categorized as viable
nd potentially eligible for resuscitation and extensive medical
ntervention, were at either ≥20 weeks gestation [16,17,24] or
22 weeks gestation [19,26,27] from studies in well-resourced
ettings. Following death, this outcome will be reported as neona-
al death. However, in countries with constraints of resources
equired to nurse extremely premature infants to a point where
hey could survive without medical intervention, live births at <28
eeks of gestational age or <1000 g birth weight are considered
on-viable, and thus deaths of these neonates would be reported
s abortions/miscarriages rather than neonatal deaths.
Maternal immunization: To report a neonatal death as an
dverse event following maternal immunization, there needs to
e evidence of vaccine administration during pregnancy. Evidence
J. Pathirana et al. / Vaay, however, vary depending on the setting (e.g. clinical trial,
ost-marketing surveillance, routine antenatal vaccination). Thus,
evels of diagnostic certainty of immunization during pregnancy
ave also been developed. Although pre-conceptual vaccinationmay  have an impact on foetal or neonatal well-being, e.g. live (viral)
vaccines, this report focuses on vaccines administered during preg-
nancy only.
1.3.7. Formulating a case deﬁnition that reﬂects diagnostic
certainty: weighing speciﬁcity versus sensitivity
It needs to be emphasized that the grading of deﬁnition levels is
entirely about diagnostic certainty, not clinical severity of an event.
Thus, a clinically very severe event, like neonatal death,  may  appro-
priately be classiﬁed as Level Two or Three rather than Level One if
it could not reasonably conﬁrm the details of the neonatal death.
As maximum speciﬁcity is normally associated with a loss of
sensitivity, two  additional diagnostic levels have been included in
the deﬁnition, offering a stepwise increase of sensitivity from Level
One down to Level Three, while retaining an acceptable level of
speciﬁcity at all levels. The aim of this stepwise categorization is
to optimize the capturing of neonatal deaths following maternal
immunization.
1.4. Guidelines for data collection, analysis and presentation
As mentioned in the overview paper [14], the case deﬁnition
is accompanied by guidelines which are structured according to
the steps of conducting a clinical trial, i.e. data collection, anal-
ysis and presentation. Neither case deﬁnition nor guidelines are
intended to guide or establish criteria for management of ill infants,
children, or adults. Both were developed to improve data compa-
rability.
The data collection guidelines are provided to enable an accurate
classiﬁcation and assessment of cause of neonatal death and in the
process assess relatedness to maternal vaccination.
1.5. Periodic review
Similar to all Brighton Collaboration case deﬁnitions and guide-
lines, review of the deﬁnition with its guidelines is planned on
a regular basis (i.e. every three to ﬁve years) or more often if
needed.
2. Case deﬁnition of neonatal death [1] and immunization
in pregnancy
For all levels of certainty, gestational age assessment should
be based on Levels of certainty for gestational age which are
being developed by the preterm delivery GAIA working group
(refer to Preterm Birth case deﬁnition available at: http://www.
brightoncollaboration.org).
2.1. Algorithm for classiﬁcation of neonatal death
34 (2016) 6027–6037 60311. Live born infant AND
2.  Gestational age <22 weeks (GA level of certainty = 1) [28] OR
3.  Birth weight <500 g AND
4.  Death of infant in ﬁrst 28 days of life AND
5.  Medically-conﬁrmed death
6032 
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Level 2 of diagnostic certainty
. Live born infant AND
.  Gestational age/size of newborn assessed as at least one of:
a.  Gestational age <22 weeks (GA Level of Certainty = 1 OR 2) [28]
b. Birth weight <500 g AND
.  Death of infant in ﬁrst 28 days of life AND
.  Medically-conﬁrmed death OR non-medically-conﬁrmed death [3]cation of neonatal death.
Level 3 of diagnostic certainty
1. Live born infant [1] AND
2.  Gestational age <5 months according to parent/family ANDmember/delivery attendant (GA Level of Certainty = 2 OR 3)
[28]
3.  Death of infant in ﬁrst 28 days of life AND
4.  Medically-conﬁrmed death [2] OR non-medically-conﬁrmed
death
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accine.3. Neonatal death in an extremely preterm live birth
MAY  apply to LMIC- or may  be non-viable in LMIC (Gestational
ge 22 to <28 weeks; should ﬁt in with GA of stillbirth deﬁnition in
egion)
Level 1 of diagnostic certainty
. Live born infant AND
. Gestational age ≥22 and <28 weeks (GA Level of
Certainty = 1) [28]
OR
.  Birth weight ≥500 g but <1000 g AND
.  Death of infant in ﬁrst 28 days of life AND
.  Medically-conﬁrmed death
Level 2 of diagnostic certainty
. Live born infant AND
.  Gestational age/size of newborn assesses as one or more of:
a. Gestational age ≥22 and <28 weeks (GA Level of
Certainty = 1 OR 2) [28]
b. Birth weight ≥500 g but <1000 g AND
.  Death of infant in ﬁrst 28 days of life AND
.  Medically-conﬁrmed death OR non-medically-conﬁrmed
death
Level 3 of diagnostic certainty
. Live born infant AND
.  Gestational age ≥5 months but <7 months according to
neonate’s parent (mother/father)/family member/delivery
attendant (GA Level of Certainty = 2 OR 3) [28]
AND
.  Death of infant in ﬁrst 28 days of life AND
.  Medically-conﬁrmed death OR non-medically-conﬁrmed
death
.4. Neonatal death in a preterm live birth (gestational age ≥28
o <37 weeks)
Level 1 of diagnostic certainty
. Live born infant AND
.  Gestational age ≥28 and <37 weeks (Level of Certainty = 1)
[28]
OR
.  Birth weight ≥1000 g but <2500 g AND
.  Death of infant in ﬁrst 28 days of life AND
.  Medically-conﬁrmed death
Level 2 of diagnostic certainty
. Live born infant AND
.  Gestational age/size of newborn assesses as one or more of:
a. Gestational age ≥28 and <37 weeks (GA Level of
Certainty = 1 OR 2) [28]
b. Birth weight ≥1000 g but <2500 g AND
.  Death of infant in ﬁrst 28 days of life AND
.  Medically-conﬁrmed death OR non-medically-conﬁrmed death
Level 3 of diagnostic certainty (MAY apply to LMIC- or may  be
on-viable in LMIC)
. Live born infant AND
.  Gestational age ≥7 months but <9 months according to
parent/family member/delivery attendant (GA Level of
Certainty = 2 OR 3) [28]
AND
.  Death of infant in ﬁrst 28 days of life AND
.  Medically-conﬁrmed death OR non-medically-conﬁrmed
death
.5. Neonatal death in a term live birth
Level 1 of diagnostic certainty
J. Pathirana et al. / V. Live born infant AND
.  Gestational age ≥37 weeks (GA Level of Certainty = 1) [28] AND
.  Birth weight >2500 g OR
. Documented intra-uterine growth retardation if ≤2500 g AND
.  Death of infant in ﬁrst 28 days of life AND
.  Medically-conﬁrmed deathLevel 2 of diagnostic certainty
1. Live born infant AND
2.  Gestational age/size of newborn assesses as one or more of:
a.  Gestational age ≥37 weeks (GA Level of Certainty = 1 OR 2)
[28]
b. Birth weight ≥2500 g AND
3.  Death of infant in ﬁrst 28 days of life AND
4.  Medically-conﬁrmed death OR non-medically-conﬁrmed
death which is conﬁrmed by examination by (by at least)
non-medically-trained attendant (e.g. undertaker,
community member)
Level 3 of diagnostic certainty (apply to LMIC)
1. Live born infant AND
2. Gestational age ≥9 months according to parent/family
member/delivery attendant (GA Level of Certainty = 2 OR 3)
[28]
AND
3.  Death of infant in ﬁrst 28 days of life AND
4.  Medically-conﬁrmed death OR non-medically-conﬁrmed
death
2.6. Levels of certainty for diagnosis of maternal immunization
Level 1 of diagnostic certainty
1. Woman  conﬁrmed as pregnant by positive pregnancy test or
ultrasound conﬁrmation
AND
2. Date/time of immunization of pregnant woman  recorded in
medical records by health care worker who
administered/witnessed administration of vaccine
AND
3. Details of vaccine, including lot number, date of
immunization
Level 2 of diagnostic certainty
1. Woman  conﬁrmed as pregnant by cessation of menstrual period and
gravid uterus
AND
2.  Date (at least month and year) of immunization of pregnant woman
recorded in medical records by health care worker who
administered/witnessed administration of vaccine
AND
3. Details of disease against which vaccinated
Level 3 of diagnostic certainty
1. Woman/medical attendant reports pregnancy AND
2.  Woman  reports receipt of vaccination during pregnancy, but no
formal recording of immunization available.
3. Guidelines for data collection, analysis and presentation
of neonatal death
It was the consensus of the Brighton Collaboration Neona-
tal death Working Group to recommend the following guidelines
to enable meaningful and standardized collection, analysis, and
presentation of information about Neonatal death. However,
implementation of all guidelines might not be possible in all sett-
ings. The availability of information may  vary depending upon
resources, geographical region, and whether the source of infor-
mation is a prospective clinical trial, a post-marketing surveillance
or epidemiological study, or an individual report of Neonatal death.
Also, as explained in more detail in the overview paper in this vol-
ume  (available at: http://www.brightoncollaboration.org), these
guidelines have been developed by this working group for guid-
ance only, and are not to be considered a mandatory requirement
for data collection, analysis, or presentation.
3.1. Data collection
These guidelines represent an ideal standard for the collec-
tion of data following immunization of pregnant women to allow
34 (2016) 6027–6037 6033for comparability of data, and are recommended as an addition
to data collected for the speciﬁc study question and setting. It is
acknowledged that not all data elements can be collected or may
be necessary. The guidelines are not intended to guide the primary
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eporting of Neonatal death to a surveillance system or study mon-
tor. Investigators developing a data collection tool based on these
ata collection guidelines also need to refer to the criteria in the
ase deﬁnition, which are not repeated in these guidelines.
Guidelines 1–38 below have been developed to address data ele-
ents for the collection of adverse event information as speciﬁed
n general drug safety guidelines by the International Conference
n Harmonization of Technical Requirements for Registration of
harmaceuticals for Human Use [29], and the form for reporting
f drug adverse events by the Council for International Orga-
izations of Medical Sciences [30]. These data elements include
n identiﬁable reporter and patient, one or more prior maternal
mmunizations, and a detailed description of the adverse event, in
his case, of Neonatal death following immunization of the mother
uring pregnancy. The additional guidelines have been developed
s guidance for the collection of additional information to allow for
 more comprehensive understanding of Neonatal death following
mmunization of the mother during pregnancy.
Data on maternal participant (vaccinee/control) AND her
nfant(s) must be collected through maternal or family member
nterview, physical examination, review of medical and other avail-
ble records as detailed further below.
.1.1. Source of information/reporter
For all cases and/or all study participants, as appropriate, the
ollowing information should be recorded:
. Date of report.
. Name and contact information of person reporting2 and/or diag-
nosing the Neonatal death as speciﬁed by country-speciﬁc data
protection law.
. Name and contact information of the investigator responsible
for the participant, as applicable.
. Relation to the maternal and neonatal participants/patient (e.g.,
immunizer [clinician, nurse], family member [indicate relation-
ship], other).
.1.2. Vaccinee/control
.1.2.1. Demographics. For all cases and/or all study participants,
s appropriate, the following information should be recorded:
. Case/study participant identiﬁers of mother and newborn (e.g.
ﬁrst name initial followed by last name initial) or code (or in
accordance with country-speciﬁc data protection laws).
. For neonates: date of birth, date of death, age at death, sex, ges-
tational age at birth, birth weight, if a twin/multiple gestation,
birth order (1st twin, 2nd twin, 3rd triplet).
For mothers: Date of birth, date of death (in case of mater-
al death), age, parity, weight, mid-upper arm circumference (if
equired).
.1.2.2. Clinical and immunization history of mother and neonate. For
ll cases and/or all study participants (maternal and neonatal), as
ppropriate, the following information should be recorded:
J. Pathirana et al. / Vac0347. Past medical history of both mother and neonate: including
hospitalisations, underlying diseases/disorders, congenital
anomalies, pre-immunization signs and symptoms including
indicators for, or the absence of, a history of allergy to vaccines,
2 If the reporting centre is different from the vaccinating centre, appropriate and
imely communication of the adverse event should occur.vaccine components or medications; food allergy; allergic
rhinitis; eczema; asthma (not exhaustive).
8. Past obstetric history: number of past pregnancies and out-
come (live births, foetal deaths, abortions), type of gestation
(singletons, multiple), pregnancy related illnesses and delivery
complications, current status of past births (surviving, died
(during neonatal period, post neonatal, under 5 death)).
9. Pregnancy details, including dates of last normal menstrual
period, ultrasound examinations, gestation, antenatal care
visits, pregnancy-related illnesses and complications (e.g.
diabetes, hypertensive disorders, febrile illnesses, substance
use/abuse, psychiatric conditions), type of gestation (singleton
or multiple).
10. Labour and delivery details, including mode of delivery, evi-
dence of infection (e.g. chorioamnionitis), complications (e.g.
foetal distress, obstructed labour, antepartum/post-partum
haemorrhage, assisted delivery) and outcome of delivery for
both maternal and infant participants (including APGAR score
(at 1 and 5 min), resuscitation requirement).
11. Any medication history (other than treatment for the event
described) prior to, during, and after immunization includ-
ing prescription and non-prescription medication as well
as medication or treatment with long half-life or long
term effect (e.g. immunoglobulins, blood transfusion and
immunosuppressant).
12. Immunization history for maternal and newborn partici-
pants (i.e. previous immunizations and any adverse event
following immunization (AEFI)), in particular occurrence of
Neonatal death after a previous immunization during previous
pregnancy.
3.1.3. Details of the immunization
For all cases and/or all study participants (maternal and neona-
tal), as appropriate, the following information should be recorded
by review of medical records or as reported by health care provider
or patient:
13. Date and time of immunization(s).
14. Description of vaccine(s) (name of vaccine, delivery system,
manufacturer, lot number, dose (e.g. 0.25 mL, 0.5 mL,  etc.) and
number of dose if part of a series of immunizations against the
same disease), type and quantity of diluent used.
15. The anatomical sites (including left or right side) of all immun-
izations (e.g. vaccine A in proximal left lateral thigh, vaccine B
in left deltoid).
16. Route and method of administration (e.g. intramuscular, intra-
dermal, subcutaneous, and needle-free (including type and
size), other injection devices).
17. Needle length and gauge.
3.1.4. The adverse event neonatal death
18. For all cases at any level of diagnostic certainty and for reported
events with insufﬁcient evidence, the criteria fulﬁlled to meet
the case deﬁnition should be recorded.
4 (2016) 6027–6037Speciﬁcally document:
19. Clinical description of signs and symptoms prior to Neonatal
death, and if there was  medical conﬁrmation of the event(s)
(i.e. neonate seen by physician).
20. Concurrent signs, symptoms, and diseases in the neonate.
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(1) Level 1: Criteria as speciﬁed in the Neonatal death case deﬁni-
tion.
(2) Level 2: Criteria as speciﬁed in the Neonatal death case deﬁni-
tion.
ccine 31. Date/time of onset symptoms3 prior to neonatal death.
2. Date and time of death.4
3. Date and time of diagnosis of death (when death met  case
deﬁnition).5
4. Date and time of reporting of death.4
5. Measurement/testing of neonate done prior to death to assess
causality.
• Values and units of routinely measured parameters (e.g. tem-
perature, blood pressure) – in particular those indicating the
severity of the event.
• Method of measurement (e.g. type of thermometer, oral or
other route, duration of measurement, etc.).
• Results of laboratory examinations, surgical and/or patholog-
ical ﬁndings, including autopsy ﬁndings and any diagnoses if
present.
6. Any treatment (includes medication administered and pro-
cedures performed, e.g. intravenous antibiotics, mechanical
ventilation, steroids) given to mother during pregnancy and to
neonate prior to the Neonatal death, especially specifying the
medication and dosing.
7. Exposures other than the immunization (either by the mother
or the neonate if also immunized) 24 h before and after immu-
nization (e.g. any medications, recreational drugs, food and
environmental exposures) considered potentially relevant to
the Neonatal death.
8. The event Neonatal Death [4] is always classiﬁed as “serious”.
.1.5. Miscellaneous/general
9. The duration of neonatal follow up until a death occurs should
be predeﬁned (e.g. for very early deaths monitor until 1 day
old, for early neonatal death monitor until 7 days of age, for all
neonatal deaths monitor until 28 days of age) based on:
• Biologic characteristics of the vaccine e.g. live attenuated
versus inactivated component vaccines; adjuvant versus
non-adjuvant vaccines.
• Biologic characteristics of the vaccine-targeted disease and
effects on infected mothers and neonates.
• Aetiology of Neonatal death(s) including patterns identiﬁed in
previous trials (e.g. early-phase trials).
• Biologic characteristics of the maternal vaccinee (e.g. nutri-
tion, underlying disease like immunosuppressive illness).
0. Methods of data collection should be consistent within and
between study groups, if applicable.
1. Investigators monitoring Neonatal deaths should provide guid-
ance to reporters to optimize the quality and completeness of
information provided.
2. Where possible, reports of Neonatal death should be collected
throughout the neonatal period regardless of the time elapsed
J. Pathirana et al. / Vabetween maternal immunization and the adverse event. If this
is not feasible due to the study design, the study periods during
which safety data are being collected should be clearly deﬁned.
3 The date and/or time of ﬁrst observation of the ﬁrst sign or symptom leading to
eonatal death can be used if date/time of neonatal death is not known.
4 The date and/or time of neonatal death is deﬁned as the date and time post
aternal immunization and subsequent birth of the neonate, when the Neonatal
eath occurred. This may  only be possible to determine in retrospect. In cases where
ate  of death is not available, date of issuance of death certiﬁcate, date of reporting
he event (from source to recipient), and date of burial should be used, whichever
s  closer to date of death.
5 An AEFI is deﬁned as serious by international standards if it meets one or
ore of the following criteria: (1) it results in death, (2) is life-threatening, (3) it
equires inpatient hospitalization or results in prolongation of existing hospitaliza-
ion, (4) results in persistent or signiﬁcant disability/incapacity, (5) is a congenital
nomaly/birth defect, (6) is a medically important event or reaction.4. Data analysis
The following guidelines represent a desirable standard for anal-
ysis of data on Neonatal death to allow for comparability of data, and
are recommended as an addition to data analyzed for the speciﬁc
study question and setting.
33. Data obtained from pregnant mothers receiving a vaccine
should be compared with those obtained from an appropriately
selected and documented control group(s) to assess back-
ground rates of neonatal death in non-exposed populations,
and should be analyzed by study arm and dose where possible,
e.g. in prospective clinical trials.
34. Reported events should be classiﬁed in one of the following
ﬁve categories which includes the three levels of diagnostic
depending on geographic setting and level of resources avail-
able. Events that meet the case deﬁnition should be classiﬁed
according to the levels of diagnostic certainty as speciﬁed in
the case deﬁnition. Events that do not meet the case deﬁnition
should be classiﬁed in the additional categories for analysis.
According to gestational age at birth of neonate event classi-
ﬁcation is in 4 categories6
A. Event meets case deﬁnition: Neonatal death in a non-viable
live birth
(1) Level 1: Criteria as speciﬁed in the Neonatal death case deﬁni-
tion.
(2) Level 2: Criteria as speciﬁed in the Neonatal death case deﬁni-
tion.
(3) Level 3: Criteria as speciﬁed in the Neonatal death case deﬁni-
tion.
Event does not meet case deﬁnitionAdditional categories for
analysis
(4) Reported Neonatal death with insufﬁcient evidence to meet the
case deﬁnition.7
(5) Not a case of Neonatal death.8
B. Event meets case deﬁnition: Neonatal death in an
extremely preterm live birth: Gestational age 22 to <28 weeks
(MAY apply to LMIC- or may  be non-viable in LMIC)
4 (2016) 6027–6037 60356 To determine the appropriate category, the user should ﬁrst establish, whether
a  reported event meets the criteria for the lowest applicable level of diagnostic
certainty, e.g. Level three. If the lowest applicable level of diagnostic certainty of
the  deﬁnition is met, and there is evidence that the criteria of the next higher level
of  diagnostic certainty are met, the event should be classiﬁed in the higher level
of  certainty category. This approach should be continued until the highest level of
diagnostic certainty for a given event could be determined. Major criteria can be used
to  satisfy the requirement of minor criteria. If the lowest level of the case deﬁnition
is  not met, it should be ruled out that any of the higher levels of diagnostic certainty
are  met  and the event should be classiﬁed in additional categories four or ﬁve.
7 If the evidence available for an event is insufﬁcient because information is
missing, such an event should be categorised as “Reported Neonatal death with
insufﬁcient evidence to meet the case deﬁnition”.
8 An event does not meet the case deﬁnition if investigation reveals a negative
ﬁnding of a necessary criterion (necessary condition) for diagnosis (e.g. not a live
birth). Such an event should be rejected and classiﬁed as “Not a case of Neonatal
death”.
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Table 1
Interval between immunization and birth, and birth and Neonatal death.
Interval between
immunization and
birth
Interval between
birth and death
Number Percentage
0–72 h 0–24 h
>24 h to 7 days
>7 to 28 days
More than 72 h to 7
days
0–24 h
>24 h to 7 days
>7 to 28 days
More than 7 days
to 30 days
0–24 h
>24 h to 7 days
>7 to 28 days
More than 30 days 0–24 h
>24 h to 7 days
cine 34 (2016) 6027–60376  
3) Level 3: Criteria as speciﬁed in the Neonatal death case deﬁni-
tion.
Event does not meet case deﬁnitionAdditional categories for
nalysis
4) Reported Neonatal death with insufﬁcient evidence to meet the
case deﬁnition.7
5) Not a case of Neonatal death.8
C. Event meets case deﬁnition: Neonatal death in a preterm
ive birth (Gestational age ≥28 to <37 weeks)
1) Level 1: Criteria as speciﬁed in the Neonatal death case deﬁni-
tion.
2) Level 2: Criteria as speciﬁed in the Neonatal death case deﬁni-
tion.
3) Level 3: Criteria as speciﬁed in the Neonatal death case deﬁni-
tion.
Event does not meet case deﬁnitionAdditional categories for
nalysis
4) Reported Neonatal death with insufﬁcient evidence to meet the
case deﬁnition [6].
5) Not a case of Neonatal death.8
D. Event meets case deﬁnition: Neonatal death in a term live
irth
1) Level 1: Criteria as speciﬁed in the Neonatal death case deﬁni-
tion.
2) Level 2: Criteria as speciﬁed in the Neonatal death case deﬁni-
tion.
3) Level 3: Criteria as speciﬁed in the Neonatal death case deﬁni-
tion.
Event does not meet case deﬁnitionAdditional categories for
nalysis
4) Reported Neonatal death with insufﬁcient evidence to meet the
case deﬁnition.7
5) Not a case of Neonatal death.8
5. The interval between immunization and reported Neonatal
death could be deﬁned as a composite of:
35.1. The date/time of immunization to the date/time of birth
AND.
35.2. Date/time of birth to date/time of neonatal death.4
If few cases are reported, the concrete time course could be ana-
lyzed for each; for a large number of cases, data can be analyzed
in the following increments:
Subjects with Neonatal death: Interval between immuniza-
ion and birth, and birth and Neonatal death (Table 1)
6. The duration of the disease process prior to Neonatal death
could be analyzed as the interval between the date/time of
onset2 of the ﬁrst symptoms and/or signs3 and the ﬁnal out-
come (neonatal death4 or 5) consistent with the case deﬁnition.
Whatever start dates are used until the death, they should be
J. Pathirana et al. / Vac036used consistently within and across study groups.
7. If more than one measurement of a particular criterion is taken
and recorded, the value corresponding to the greatest magni-
tude of the adverse experience could be used as the basis for>7 to 28 days
Total
analysis. Analysis may  also include other characteristics like
qualitative patterns of criteria deﬁning the event.
38. The distribution of data (as numerator and denominator data)
could be analyzed in predeﬁned increments (e.g. measured
values, times), where applicable. Increments speciﬁed above
should be used. When only a small number of cases is pre-
sented, the respective values or time course can be presented
individually.
4.1. Data presentation
These guidelines represent a desirable standard for the pre-
sentation and publication of data on Neonatal death following
immunization of infant’s mother to allow for comparability of data,
and are recommended as an addition to data presented for the spe-
ciﬁc study question and setting. Additionally, it is recommended to
refer to existing general guidelines for the presentation and pub-
lication of randomized controlled trials, systematic reviews, and
meta-analyses of observational studies in epidemiology (e.g. state-
ments of Consolidated Standards of Reporting Trials (CONSORT)
[31], of Improving the quality of reports of meta-analyses of ran-
domized controlled trials (QUORUM) [32], and of Meta-analysis
Of Observational Studies in Epidemiology (MOOSE) [33], respec-
tively.
39. All reported events of Neonatal death should be presented
according to the categories listed in guideline 34.
40. Data on Neonatal death events should be presented in accor-
dance with data collection guidelines 1–32 and data analysis
guidelines 33–44.
41. Data should be presented with numerator and denominator
(n/N) (and not only in percentages), if available.
Although immunization safety surveillance systems denom-
inator data are usually not readily available, attempts should
be made to identify approximate denominators. The source
of the denominator data should be reported and calculations
of estimates be described (e.g. manufacturer data like total
doses distributed, reporting through Ministry of Health, cov-
erage/population based data, etc.).
42. The incidence of cases in the study population should be pre-
sented and clearly identiﬁed as such in the text.
43. If the distribution of data is skewed, median and inter-quartile
range are usually the more appropriate statistical descriptors
than a mean. However, the mean and standard deviation should
also be provided.
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ccine 34. Any publication of data on Neonatal death should include a
detailed description of the methods used for data collection
and analysis as possible. It is essential to specify:
• The study design.
• The method, frequency and duration of monitoring for
Neonatal death.
• The trial proﬁle, indicating participant ﬂow during a study
including drop-outs and withdrawals to indicate the size and
nature of the respective groups under investigation.
• The type of surveillance (e.g. passive or active surveillance).
• The characteristics of the surveillance system (e.g. population
served, mode of report solicitation).
• The search strategy in surveillance databases.
• Comparison group(s), if used for analysis.
• The instrument of data collection (e.g. standardized question-
naire, diary card, report form).
• Whether the day of maternal immunization was  considered
“day one” or “day zero” in the analysis.
• Whether the date the neonatal death occurred4 and/or the
date of ﬁrst observation of ﬁrst symptoms leading to neonatal
death3 used for analysis.
• Use of this case deﬁnition for Neonatal death, in the abstract
or methods section of a publication.9
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